CN1270763C - 化瘀固精制剂及其制备方法和用途 - Google Patents
化瘀固精制剂及其制备方法和用途 Download PDFInfo
- Publication number
- CN1270763C CN1270763C CN 200310116253 CN200310116253A CN1270763C CN 1270763 C CN1270763 C CN 1270763C CN 200310116253 CN200310116253 CN 200310116253 CN 200310116253 A CN200310116253 A CN 200310116253A CN 1270763 C CN1270763 C CN 1270763C
- Authority
- CN
- China
- Prior art keywords
- preparation
- astringent drugs
- nocturnal emission
- controlling nocturnal
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 78
- 210000004369 blood Anatomy 0.000 title claims abstract description 63
- 239000008280 blood Substances 0.000 title claims abstract description 63
- 210000003734 kidney Anatomy 0.000 title abstract description 16
- 201000007094 prostatitis Diseases 0.000 claims abstract description 11
- 239000007788 liquid Substances 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims description 108
- 229940079593 drug Drugs 0.000 claims description 81
- 206010059013 Nocturnal emission Diseases 0.000 claims description 68
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- 241001057584 Myrrha Species 0.000 claims description 10
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 9
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 241000283956 Manis Species 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 6
- 210000000582 semen Anatomy 0.000 claims description 6
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 5
- 239000004378 Glycyrrhizin Substances 0.000 claims description 5
- 230000006837 decompression Effects 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 5
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 5
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 5
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 5
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 5
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 5
- 239000004302 potassium sorbate Substances 0.000 claims description 5
- 235000010241 potassium sorbate Nutrition 0.000 claims description 5
- 229940069338 potassium sorbate Drugs 0.000 claims description 5
- 238000004064 recycling Methods 0.000 claims description 5
- 238000007796 conventional method Methods 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000019634 flavors Nutrition 0.000 claims description 3
- 239000006186 oral dosage form Substances 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 16
- 230000001737 promoting effect Effects 0.000 abstract description 14
- 210000002307 prostate Anatomy 0.000 abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 6
- 244000208060 Lawsonia inermis Species 0.000 abstract description 5
- 230000017531 blood circulation Effects 0.000 abstract description 5
- 230000027939 micturition Effects 0.000 abstract description 4
- 239000007787 solid Substances 0.000 abstract description 3
- -1 urgent urination Diseases 0.000 abstract description 3
- 206010020718 hyperplasia Diseases 0.000 abstract description 2
- 210000003127 knee Anatomy 0.000 abstract description 2
- 241000427159 Achyranthes Species 0.000 abstract 1
- 240000007311 Commiphora myrrha Species 0.000 abstract 1
- 235000006965 Commiphora myrrha Nutrition 0.000 abstract 1
- 241000510667 Conioselinum Species 0.000 abstract 1
- 240000009138 Curcuma zedoaria Species 0.000 abstract 1
- 235000003405 Curcuma zedoaria Nutrition 0.000 abstract 1
- 241000735527 Eupatorium Species 0.000 abstract 1
- 241000218231 Moraceae Species 0.000 abstract 1
- 235000008708 Morus alba Nutrition 0.000 abstract 1
- 235000007265 Myrrhis odorata Nutrition 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 241000283966 Pholidota <mammal> Species 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 244000178320 Vaccaria pyramidata Species 0.000 abstract 1
- 235000010587 Vaccaria pyramidata Nutrition 0.000 abstract 1
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 abstract 1
- 206010013990 dysuria Diseases 0.000 abstract 1
- 210000001624 hip Anatomy 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 230000035943 smell Effects 0.000 abstract 1
- 235000019640 taste Nutrition 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- 235000019509 white turmeric Nutrition 0.000 abstract 1
- 230000001276 controlling effect Effects 0.000 description 65
- 241000699670 Mus sp. Species 0.000 description 34
- 230000008859 change Effects 0.000 description 29
- 230000037396 body weight Effects 0.000 description 26
- 238000000034 method Methods 0.000 description 20
- 210000002966 serum Anatomy 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 15
- 241000700159 Rattus Species 0.000 description 13
- 206010042674 Swelling Diseases 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 230000008961 swelling Effects 0.000 description 13
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 230000036407 pain Effects 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 description 10
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 10
- 230000003203 everyday effect Effects 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 9
- 239000007789 gas Substances 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 239000013641 positive control Substances 0.000 description 9
- 102000016943 Muramidase Human genes 0.000 description 8
- 108010014251 Muramidase Proteins 0.000 description 8
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 8
- 229960001138 acetylsalicylic acid Drugs 0.000 description 8
- 239000004325 lysozyme Substances 0.000 description 8
- 235000010335 lysozyme Nutrition 0.000 description 8
- 229960000274 lysozyme Drugs 0.000 description 8
- 206010018691 Granuloma Diseases 0.000 description 7
- 241000193830 Bacillus <bacterium> Species 0.000 description 6
- 241000588769 Proteus <enterobacteria> Species 0.000 description 6
- 229920001525 carrageenan Polymers 0.000 description 6
- 235000010418 carrageenan Nutrition 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 206010033971 Paratyphoid fever Diseases 0.000 description 5
- 208000037386 Typhoid Diseases 0.000 description 5
- 230000000202 analgesic effect Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 241000411851 herbal medicine Species 0.000 description 5
- 230000000422 nocturnal effect Effects 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000001502 supplementing effect Effects 0.000 description 5
- 239000003440 toxic substance Substances 0.000 description 5
- 201000008297 typhoid fever Diseases 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 244000111489 Gardenia augusta Species 0.000 description 4
- 108010006464 Hemolysin Proteins Proteins 0.000 description 4
- 206010020880 Hypertrophy Diseases 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000003228 hemolysin Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 229940090044 injection Drugs 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 231100000682 maximum tolerated dose Toxicity 0.000 description 4
- 210000002460 smooth muscle Anatomy 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 240000001624 Espostoa lanata Species 0.000 description 3
- 235000009161 Espostoa lanata Nutrition 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 210000000436 anus Anatomy 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 230000004089 microcirculation Effects 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- 210000000626 ureter Anatomy 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 239000006916 nutrient agar Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 240000004528 Catalpa ovata Species 0.000 description 1
- 235000010005 Catalpa ovata Nutrition 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241000201295 Euphrasia Species 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 231100000460 acute oral toxicity Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000010165 autogamy Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 208000013507 chronic prostatitis Diseases 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 229940108605 cyclophosphamide injection Drugs 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 238000004134 energy conservation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000033687 granuloma formation Effects 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 208000010553 multiple abscesses Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 235000020995 raw meat Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000013337 sub-cultivation Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000476 thermogenic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
组别 | n | 剂量(ml/kg.qd×30) | 前列腺湿重(mg) | 前列腺干重(mg) | 增生抑制率(%) |
对照组前列康组化淤固精合剂组 | 1010101010 | 9.02.0g1.03.09.0 | 226.7±50.5188.3±22.3*165.7±27.0**++161.7±46.7**++125.0±18.7***+++ | 136.0±30.3113.0±13.4*99.4±16.2**+97.0±28.0***+75.0±11.2***+++ | -17272945 |
组别 | 剂量(ml/kg.qd×6) | 足跖肿胀度(mm) | |||
1h | 2h | 3h | 4h | ||
对照组(NS)前列康组化淤固精合剂组 | 202.0g102030 | 0.44±0.150.46±0.11*0.44±0.20*0.40±0.08*0.32±0.11* | 0.67±0.120.67±0.09*0.69±0.08*+0.62±0.12*++0.53±0.09***+++ | 0.87±0.140.78±0.009*0.83±0.08*+0.71±0.04***+++0.73±0.15**++ | 0.86±0.100.74±0.04***0.79±0.16*+0.71±0.14**+0.74±0.03***+ |
组别 | n | 剂量(ml/kg.qd×5) | 耳壳肿胀度(mg) |
对照组(NS)前列康片组化淤固精合剂组 | 1010101010 | 202.0g102030 | 11.08±1.648.37±1.71***8.37±2.29**+7.68±2.15***+8.28±1.12***+ |
组别 | n(双侧) | 剂量(ml/kg.qd×7) | 棉球肉芽肿重(mg/100g) | 抑制率 |
对照组(ws)前列康组化淤固精合剂组 | 88888 | 62.0g2618 | 83.76±36.6051.16±24.36**46.65±23.79***+39.38±30.97***++21.05±13.30***+++ | -39445375 |
组别 | 剂量(ml/kg.qd×4) | 给药后各时降温数(℃) | |||
30’ | 60’ | 120’ | 180’ | ||
对照组阿斯匹林组前列宁组 | 100.15g51015 | 0.63±0.111.03±0.25**0.20±0.14**++0.46±0.30*+0.76±0.21*+ | 0.40±0.171.26±0.61**1.00±0.01***+0.83±0.25**++0.86±0.05***++ | 0.66±0.301.43±1.01*1.45±0.07**+1.40±0.15***+1.46±0.14***+ | 1.13±0.081.56±0.56*2.20±0.28***++1.90±0.11***+1.36±0.90*+ |
组别 | 剂量(ml/kg.qd×7) | 痛反应潜伏期(秒) | 阈痛提高%(45分钟) | ||
药前 | 药后15分钟 | 药后45分钟 | |||
对照组(NS)阿斯匹林组前列宁组 | 200.2g102030 | 20.12±2.8021.50±2.7021.00±2.5019.00±3.2020.75±2.90 | 21.75±3.0021.37±3.10*21.62±3.20*+23.50±4.17*+22.00±3.40*+ | 21.25±5.4033.10±5.80***27.12±3.70***+28.25±5.60***+28.00±4.70***+ | -54294935 |
组别 | n | 剂量(ml/kg.qd×7) | 15分钟内扭体次数 |
对照组(NS)阿斯匹林组化淤固精合剂组 | 1010101010 | 200.2g102030 | 21.15±3.909.50±4.60***25.50±9.10*23.80±6.70*20.37±5.90* |
稀释度菌种 | 原液 | 1∶2 | 1∶4 | 1∶8 | 1∶16 | 1∶32 | 1∶64 | 1∶128 | 1∶256 | 对照 |
大肠杆菌变形杆菌 | -- | -- | -- | -- | ±- | +± | ++ | ++ | ++ | ++ |
稀释度菌种 | 原液 | 1∶2 | 1∶4 | 1∶8 | 1∶16 |
大肠杆菌变形杆菌 | -- | -- | -- | ++ | + |
组别 | n | 剂量(ml/kg.qd×9) | HC50 |
对照组(NS)环磷酰胺组化淤固精合剂组 | 1010101010 | 2020mg102030 | 139.34±20.3671.32±21.05***143.59±19.67*+++168.83±18.11***+++177.35±29.58***+++ |
组别 | n | 剂量(ml/kg.qd×7) | 血清溶菌酶含量(ug/ml) |
生理盐水对照组地塞米松组化淤固精合剂组 | 1010101010 | 202.5g102030 | 3.49±1.122.12±0.62***4.46±0.12**+++4.93±1.09**+++4.59±0.83**+++ |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200310116253 CN1270763C (zh) | 2003-11-14 | 2003-11-14 | 化瘀固精制剂及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200310116253 CN1270763C (zh) | 2003-11-14 | 2003-11-14 | 化瘀固精制剂及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1615932A CN1615932A (zh) | 2005-05-18 |
CN1270763C true CN1270763C (zh) | 2006-08-23 |
Family
ID=34760621
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200310116253 Expired - Lifetime CN1270763C (zh) | 2003-11-14 | 2003-11-14 | 化瘀固精制剂及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1270763C (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100374663C (zh) * | 2004-12-30 | 2008-03-12 | 中国科学院沈阳自动化研究所 | 自走式海缆埋设机用链式挖掘工具 |
EP3721891A4 (en) * | 2017-12-06 | 2021-06-09 | Helixmith Co., Ltd | HERBAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF BENIGNER PROSTATE HYPERPLASIA |
-
2003
- 2003-11-14 CN CN 200310116253 patent/CN1270763C/zh not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN1615932A (zh) | 2005-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103251873B (zh) | 一种消食化积的中兽药 | |
CN103238756A (zh) | 一种育肥猪配合饲料及其制备方法 | |
CN104187172B (zh) | 用于治疗乌龟肠胃炎病的功能性饲料及其制备方法 | |
CN1305513C (zh) | 一种广谱治疗癌症的中药制剂及其制备方法 | |
CN1289137C (zh) | 一种治疗乳腺增生疾病的药物和制备方法及其应用 | |
CN1927322A (zh) | 治疗急慢性前列腺炎的脂溶性中药栓剂及其生产工艺 | |
CN1709302A (zh) | 治疗慢性盆腔炎的中药制剂及其制备方法 | |
CN104147518A (zh) | 一种治疗抑郁症的中药胶囊及其制备方法 | |
CN1270763C (zh) | 化瘀固精制剂及其制备方法和用途 | |
CN1840160A (zh) | 抗骨质增生粉 | |
CN104189413A (zh) | 用于治疗乌龟肠胃炎病的药物组合物及其制备方法 | |
CN1899560A (zh) | 一种用于治疗暑湿型感冒的复方制剂及其制备方法 | |
CN1739678A (zh) | 一种治疗风寒湿痹症疼痛的药物及其制备方法 | |
CN1298351C (zh) | 一种治疗泌尿系感染的中药口服制剂及其制备方法 | |
CN1537564A (zh) | 一种广谱治疗癌症的中药制剂 | |
CN1733290A (zh) | 一种治疗急慢性胆囊炎、胆石症的药物及其制备方法与应用 | |
CN101066294A (zh) | 一种补肾散寒止湿缩尿的中药制剂及其制备方法 | |
CN1269501C (zh) | 一种治疗慢性结肠炎的药物及制备方法 | |
CN1100550C (zh) | 一种适用于各种癌症的中药组合物 | |
CN1718578A (zh) | 独活提取物、其制备方法及含有该提取物的药物 | |
CN103876207B (zh) | 治疗肿瘤患者术后便秘的保健汤及其制备方法 | |
CN107029067B (zh) | 一种抗人类乳头瘤病毒的复方中药制剂及制备方法 | |
CN1943701A (zh) | 一种治疗非淋菌性尿道炎的药物及其制备方法 | |
CN1927349A (zh) | 一种治疗痹症的中药及其制备方法 | |
CN101053624A (zh) | 一种治疗前列腺增生、慢性前列腺炎的中药及其制备工艺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: XINJIANG QIKANG HABO UIGUR MEDICINE CO., LTD. Free format text: FORMER NAME: QIKANGHABO UYGUR MEDICINE CO., LTD., XINJIANG |
|
CP03 | Change of name, title or address |
Address after: 830026 No. 625 Yingbin Road, the Xinjiang Uygur Autonomous Region, Urumqi Patentee after: XINJIANG QIKANG HABO UIGHUR MEDICINE CO.,LTD. Address before: 830001 No. 36, Yanan Road, Urumqi, the Xinjiang Uygur Autonomous Region Patentee before: QIKANGHABO UGGR MEDICINE Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 830000 the Xinjiang Uygur Autonomous Region Urumqi hi tech Industrial Development Zone (new urban area) 1375 Patentee after: New Qikang Pharmaceutical Co.,Ltd. Address before: 830026 Yingbin Road, Urumqi, the Xinjiang Uygur Autonomous Region 625 Patentee before: XINJIANG QIKANG HABO UIGHUR MEDICINE CO.,LTD. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20060823 |